Search | Clinical Trials Finder

Conditions: Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Bipolar Type I Disorder, Bipolar Disorder Mild, Bipolar Disorder Moderate, Bipolar Disorder Severe
Interventions: No intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Anxiety Disorders, Stress Disorders, Post-Traumatic, Pregnancy, High Risk, Depressive Disorder, Major, Pregnancy Complications, ADHD - Attention Deficit Disorder With Hyperactivity
Interventions: Collaborative Mental Health Care Program (CMHCP); Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Major Depression
Interventions: D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo; Drug · Device
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Depressive Disorder, Major Depressive Disorder, Dysthymic Disorder, Alcohol-Related Disorders, Alcoholism
Interventions: Cognitive Behavioral Analysis System of Psychotherapy; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Depression, Anxiety
Interventions: Not listed
Lead sponsor: Assurex Health Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anxiety Disorder, Major Depressive Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Desipramine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder
Interventions: Placebo, fluoxetine, duloxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 44
States / cities: Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more

Conditions: Multiple Sclerosis, Major Depressive Disorder
Interventions: POWER-MS, FLEX-MS; Behavioral
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 64 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression, Major Depressive Disorder, Major Depression
Interventions: Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions; Device · Other · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
Interventions: Ketamine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Major Depression, Anxiety Disorder
Interventions: Problem-Solving Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Depressive Disorder, Major
Interventions: Esketamine nasal spray; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Major Depressive Disorder
Interventions: Aripiprazole 5mg, Aripiprazole 2mg, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions: HT-2157, Placebo; Drug
Lead sponsor: Dart NeuroScience, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Depressive Disorder, Major
Interventions: orvepitant, placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Arcadia, California + 14 more

Conditions: Human Immunodeficiency Virus, Neurocognitive Impairment
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 25 Years to 61 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Involutional Depression, Anxiety Disorders
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 10 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Traumatic Brain Injury
Interventions: Amantadine Hydrochloride, Placebo; Drug
Lead sponsor: JFK Medical Center; Other
Eligibility: 16 Years to 65 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 8
States / cities: Braintree, Massachusetts • Jackson, Mississippi • New York, New York + 5 more

Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder, Transcranial Magnetic Stimulation, Repetitive
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Major Depressive Disorder
Interventions: PDC-1421 Capsule; Drug
Lead sponsor: BioLite, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, Asparagine Synthetase Deficiency, CHARGE Syndrome, Early Infantile Epileptic Encephalopathy, FOXG1 Syndrome, KBG Syndrome, Noonan Syndrome, Severe Hemophilia A, Short Bowel Syndrome, Beta-Propeller Protein-Associated Neurodegeneration, Brain Injury of Prematurity With Periventricular Leukomalacia, Chromosome 17p13.3 Microdeletion Syndrome, Chromosome 1q43-1q44 Deletion, Cockayne Syndrome, Congenital Diaphragmatic Hernia, End-Stage Renal Disease With Cloacal Anomaly, Mitochondrial Depletion Disorder, Severe Factor VII Deficiency
Interventions: Family Centered pediatric palliative care for family caregivers of children with rare diseases.; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 12 Months to 99 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder

MOCHA: Embedded Inpatient Mental Health Care for High-Risk Perinatal Patients

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence

Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX

Depression, Epinephrine, and Platelet Function

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Translational Investigation of Gestational Environment on Neurobehavioral Function in Children

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

Depression Agency-Based Collaboration

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

Brain Network Dynamics of Depression During Esketamine Treatment

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Brain Imaging for HIV-Associated Thinking and Mood Disorders

MRI Study of Brain Activity and Risk for Depression in Adolescents

Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)

rTMS for PTSD Comorbid With Major Depressive Disorder

A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

Palliative Care Needs of Children With Rare Diseases and Their Families